Transcriptomic analyses identify association between mitotic kinases, PDZ-binding kinase and BUB1, and clinical outcome in breast cancer

Breast Cancer Research and Treatment

Volumn 156, Issue 1, 2016, Pages 1-8

  Ocaña, Alberto ^a   Pérez Peña, Javier ^a   Díez González, Laura ^a   Sánchez Corrales, Verónica ^a   Templeton, Arnoud ^b   Seruga, Bostjan ^c   Amir, Eitan ^d   Pandiella, Atanasio ^e  

^a HOSPITAL GENERAL UNIVERSITARIO DE ALBACETE   (Spain)

^b CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^c INSTITUTE OF ONCOLOGY   (Slovenia)

^d UNIVERSITY OF TORONTO   (Canada)

^e UNIVERSITY OF SALAMANCA   (Spain)

Author keywords

Breast cancer; BUB1; Mitotic kinases; PDZ binding kinase

Indexed keywords

BUB1 BETA PROTEIN; BUB1 PROTEIN; MITOTIC KINASE; PDZ BINDING KINASE; PROTEIN KINASE; TRANSCRIPTOME; TUMOR PROTEIN; UNCLASSIFIED DRUG; BUB1 PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PDZ-BINDING KINASE; PROTEIN SERINE THREONINE KINASE;

ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; BUB1 BETA GENE; CANCER PROGNOSIS; CANCER SURVIVAL; CELL CYCLE REGULATION; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; ENZYME ACTIVITY; ENZYME ASSAY; GENE FUNCTION; GENE IDENTIFICATION; HUMAN; MOLECULAR PATHOLOGY; ONCOGENE; OVERALL SURVIVAL; PDZ BINDING KINASE GENE; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECURRENCE FREE SURVIVAL; SIGNAL TRANSDUCTION; UPREGULATION; BASAL CELL CARCINOMA; BREAST TUMOR; COMPUTER SIMULATION; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC DATABASE; GENETICS; PATHOLOGY; PROCEDURES; PROGNOSIS; SURVIVAL ANALYSIS;

BREAST NEOPLASMS; COMPUTER SIMULATION; DATABASES, GENETIC; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; NEOPLASMS, BASAL CELL; PROGNOSIS; PROTEIN-SERINE-THREONINE KINASES; SURVIVAL ANALYSIS; UP-REGULATION;

EID: 84961195048     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-016-3720-4     Document Type: Article

References (22)

1. Le Du F, Eckhardt BL, Lim B, Litton JK, Moulder S, Meric-Bernstam F, Gonzalez-Angulo AM, Ueno NT (2015) Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype? Oncotarget 6(15):12890–12908
2. Ocana A, Pandiella A (2008) Identifying breast cancer druggable oncogenic alterations: lessons learned and future targeted options. Clin Cancer Res 14(4):961–970. doi:10.1158/1078-0432.CCR-07-1630
3. Blume-Jensen P, Hunter T (2001) Oncogenic kinase signalling. Nature 411(6835):355–365. doi:10.1038/35077225
4. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S (2002) The protein kinase complement of the human genome. Science 298(5600):1912–1934. doi:10.1126/science.1075762
5. Ocana A, Amir E, Seruga B, Martin M, Pandiella A (2013) The evolving landscape of protein kinases in breast cancer: clinical implications. Cancer Treat Rev 39(1):68–76. doi:10.1016/j.ctrv.2012.05.004
6. Montero JC, Esparis-Ogando A, Re-Louhau MF, Seoane S, Abad M, Calero R, Ocana A, Pandiella A (2014) Active kinase profiling, genetic and pharmacological data define mTOR as an important common target in triple-negative breast cancer. Oncogene 33(2):148–156. doi:10.1038/onc.2012.572
7. Ortiz-Ruiz MJ, Alvarez-Fernandez S, Parrott T, Zaknoen S, Burrows FJ, Ocana A, Pandiella A, Esparis-Ogando A (2014) Therapeutic potential of ERK5 targeting in triple negative breast cancer. Oncotarget 5(22):11308–11318
8. Al-Ejeh F, Simpson PT, Saunus JM, Klein K, Kalimutho M, Shi W, Miranda M, Kutasovic J, Raghavendra A, Madore J, Reid L, Krause L, Chenevix-Trench G, Lakhani SR, Khanna KK (2014) Meta-analysis of the global gene expression profile of triple-negative breast cancer identifies genes for the prognostication and treatment of aggressive breast cancer. Oncogenesis 3:e124. doi:10.1038/oncsis.2014.41
9. Cuenca-Lopez MD, Serrano-Heras G, Montero JC, Corrales-Sanchez V, Gomez-Juarez M, Gascon-Escribano MJ, Morales JC, Voisin V, Nunez LE, Moris F, Bader GD, Pandiella A, Ocana A (2015) Antitumor activity of the novel multi-kinase inhibitor EC-70124 in triple negative breast cancer. Oncotarget 6(29):27923
10. Maire V, Nemati F, Richardson M, Vincent-Salomon A, Tesson B, Rigaill G, Gravier E, Marty-Prouvost B, De Koning L, Lang G, Gentien D, Dumont A, Barillot E, Marangoni E, Decaudin D, Roman-Roman S, Pierre A, Cruzalegui F, Depil S, Tucker GC, Dubois T (2013) Polo-like kinase 1: a potential therapeutic option in combination with conventional chemotherapy for the management of patients with triple-negative breast cancer. Cancer Res 73(2):813–823. doi:10.1158/0008-5472.CAN-12-2633
11. Maire V, Baldeyron C, Richardson M, Tesson B, Vincent-Salomon A, Gravier E, Marty-Prouvost B, De Koning L, Rigaill G, Dumont A, Gentien D, Barillot E, Roman-Roman S, Depil S, Cruzalegui F, Pierre A, Tucker GC, Dubois T (2013) TTK/hMPS1 is an attractive therapeutic target for triple-negative breast cancer. PLoS One 8(5):e63712. doi:10.1371/journal.pone.0063712
12. Maia AR, de Man J, Boon U, Janssen A, Song JY, Omerzu M, Sterrenburg JG, Prinsen MB, Willemsen-Seegers N, de Roos JA, van Doornmalen AM, Uitdehaag JC, Kops GJ, Jonkers J, Buijsman RC, Zaman GJ, Medema RH (2015) Inhibition of the spindle assembly checkpoint kinase TTK enhances the efficacy of docetaxel in a triple-negative breast cancer model. Ann Oncol. doi:10.1093/annonc/mdv293
13. Chu Z, Lin H, Liang X, Huang R, Tang J, Bao Y, Jiang J, Zhan Q, Zhou X (2015) Association between axillary lymph node status and Ki67 labeling index in triple-negative medullary breast carcinoma. Jpn J Clin Oncol 45(7):637–641. doi:10.1093/jjco/hyv052
14. Richardson AL, Wang ZC, De Nicolo A, Lu X, Brown M, Miron A, Liao X, Iglehart JD, Livingston DM, Ganesan S (2006) X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell 9(2):121–132. doi:10.1016/j.ccr.2006.01.013
15. Gyorffy B, Surowiak P, Budczies J, Lanczky A (2013) Online survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung cancer. PLoS One 8(12):e82241. doi:10.1371/journal.pone.0082241
16. http://kmplot.com/analysis/index.php?p=service&cancer=breast. Accessed 8 Jan 2016
17. Li W, Lan Z, Wu H, Wu S, Meadows J, Chen J, Zhu V, Dai W (1999) BUBR1 phosphorylation is regulated during mitotic checkpoint activation. Cell Growth Differ 10(11):769–775
18. Kang J, Yang M, Li B, Qi W, Zhang C, Shokat KM, Tomchick DR, Machius M, Yu H (2008) Structure and substrate recruitment of the human spindle checkpoint kinase Bub1. Mol Cell 32(3):394–405. doi:10.1016/j.molcel.2008.09.017
19. Klebig C, Korinth D, Meraldi P (2009) Bub1 regulates chromosome segregation in a kinetochore-independent manner. J Cell Biol 185(5):841–858. doi:10.1083/jcb.200902128
20. Gaudet S, Branton D, Lue RA (2000) Characterization of PDZ-binding kinase, a mitotic kinase. Proc Natl Acad Sci USA 97(10):5167–5172. doi:10.1073/pnas.090102397
21. Zhao S, Dai J, Zhao W, Xia F, Zhou Z, Wang W, Gu S, Ying K, Xie Y, Mao Y (2001) PDZ-binding kinase participates in spermatogenesis. Int J Biochem Cell Biol 33(6):631–636
22. Simons-Evelyn M, Bailey-Dell K, Toretsky JA, Ross DD, Fenton R, Kalvakolanu D, Rapoport AP (2001) PBK/TOPK is a novel mitotic kinase which is upregulated in Burkitt’s lymphoma and other highly proliferative malignant cells. Blood Cells Mol Dis 27(5):825–829. doi:10.1006/bcmd.2001.0452